|
3-year local failure-free rate
|
3-year overall survival rate
|
---|
|
SRS
|
SRM
|
p value
|
SRS
|
SRM
|
p value
|
Sex
| | | | | | |
male
|
54%
|
87%
|
0.006
|
63%
|
63%
|
0.806
|
female
|
42%
|
73%
|
0.275
|
75%
|
24%
|
0.067
|
Age
| | | | | | |
≤ 45
|
27%
|
87%
|
0.023
|
63%
|
44%
|
0.338
|
> 45
|
49%
|
80%
|
0.028
|
67%
|
62%
|
0.702
|
Type of failure
| | | | | | |
persistent disease
|
77%
|
94%
|
0.456
|
87%
|
90%
|
0.589
|
recurrent disease
|
30%
|
75%
|
0.001
|
52%
|
35%
|
0.419
|
rT stage
| | | | | | |
rT1
|
69%
|
88%
|
0.133
|
85%
|
79%
|
0.721
|
rT2-4
|
28%
|
78%
|
0.006
|
45%
|
28%
|
0.458
|
Tumor volume
| | | | | | |
≤ 5 cc
|
62%
|
90%
|
0.219
|
79%
|
75%
|
0.502
|
> 5 – 10 cc
|
61%
|
67%
|
0.342
|
78%
|
44%
|
0.117
|
> 10 cc
|
69%
|
84%
|
0.106
|
25%
|
52%
|
0.108
|
- SRS: stereotactic radiotherapy using single fracton
- SRM: stereotactic radiotherapy using multiple fractions